This failure in translation from bench to bedside has led to the recommendations on the stroke therapy academic industry roundtable (STAIR),27 even though clinical trials fulfilling the STAIR criteria for EPO or G-CSTS did not confirm preclinical experimentation as well.28 The reasons for this failure are multifarious, ranging from the plurality of mechanisms of cell death,29 the side effects of activity blockade to prevent excitotoxicity and the general conditions of the patient due to comorbidities. Here, EPO is linked to Stroke.